Provided by Tiger Trade Technology Pte. Ltd.

bioAffinity Technologies, Inc.

10.50
+1.5717.58%
Pre-market: 10.47-0.0310-0.30%05:31 EDT
Volume:10.46M
Turnover:115.70M
Market Cap:6.22M
PE:-0.10
High:12.32
Open:10.90
Low:10.09
Close:8.93
52wk High:202.50
52wk Low:4.56
Shares:592.37K
Float Shares:586.87K
Volume Ratio:0.39
T/O Rate:1781.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-103.3536
EPS(LYR):-129.9452
ROE:-1860.15%
ROA:-125.11%
PB:1.65
PE(LYR):-0.08

Loading ...

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 13

Heron Therapeutics Q2 Revenue Rises on Acute Care Growth, Withdraws 2026 Outlook

Reuters
·
Aug 10

bioAffinity Technologies Q2 Net Income USD -3.4 Million

THOMSON REUTERS
·
Aug 07

bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate

Benzinga Earnings
·
Aug 07

bioAffinity Q2 FY26 Net Loss Narrows to $3.4 Million; Revenue Rises 19% to $1.5 Million

Reuters
·
Aug 07

Press Release: bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

Dow Jones
·
Aug 07

bioAffinity Technologies Faces NASDAQ Delisting Risk After Shares Trade Below $1 Bid-price Minimum

Reuters
·
Aug 01

BioAffinity announces publication of clinical review on CyPath Lung

TIPRANKS
·
Jul 27

bioAffinity Publishes Clinical Framework Targeting Pulmonary Nodule Risk Stratification Market

Reuters
·
Jul 27

Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia

THOMSON REUTERS
·
Jul 22

Bioaffinity Technologies - Partners with Pictor to Develop Asthma and Copd Diagnostics

THOMSON REUTERS
·
Jul 22

Bioaffinity Quarterly Cypath Lung Test Sales Double, up More than 200% Year over Year

Reuters
·
Jul 07

Bioaffinity to Join Navref-hosted Webinar on Philips-led US Veterans Lung Screening Program

Reuters
·
Jul 01

BioAffinity will present preclinical findings on small interfering RNAs

TIPRANKS
·
Jun 22

bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells

Reuters
·
Jun 22

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

THOMSON REUTERS
·
Jun 22

BioAffinity Technologies Closes $3.2 Million Public Offering

MT Newswires Live
·
Jun 19

bioAffinity Technologies closes USD 3.2 million follow-on offering priced at USD 0.8 per share

Reuters
·
Jun 19

bioAffinity Technologies Announces Closing of $3.2 Million Offering

THOMSON REUTERS
·
Jun 19

bioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%

MT Newswires Live
·
Jun 17